Related Experiment Video

Updated: May 13, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K

miR-126-5p suppresses HeLa and Ishikawa cell proliferation and migration via the RICTOR/AKT pathway

Xuan Zhang1, Yanjing Yang2, Yaqin Li1

  • 1Department of Obstetrics, Shijiazhuang Obstetrics and Gynecology Hospital, Shijiazhuang, 050011, Hebei Province, China.

Discover Oncology
|April 16, 2025
PubMed
Abstract

Insights

MicroRNA-126-5p (miR-126-5p) significantly inhibits uterine cancer cell growth and promotes cell death. This microRNA shows promise as a novel therapeutic target for improving uterine cancer treatment outcomes.

Area of Science:

  • Gynecological oncology
  • Molecular biology
  • Cancer research

Background:

  • Uterine cancer presents increasing incidence and mortality.
  • Current treatments face challenges due to tumor heterogeneity and resistance.
  • Novel therapeutic targets are urgently needed for uterine cancer.

Purpose of the Study:

  • To investigate the role of miR-126-5p in uterine cancer pathogenesis.
  • To evaluate miR-126-5p as a potential therapeutic target.
  • To explore the molecular mechanisms of miR-126-5p in uterine cancer.

Main Methods:

  • Utilized HeLa and Ishikawa cell lines.
  • Assessed the impact of miR-126-5p on cell proliferation, migration, and apoptosis.
  • Investigated the involvement of the RICTOR/AKT signaling pathway.

Main Results:

  • miR-126-5p significantly inhibited cell proliferation and migration.
  • miR-126-5p significantly promoted apoptosis in cancer cells.
  • These effects were mediated by the RICTOR/AKT signaling pathway.

Conclusions:

  • miR-126-5p is a critical regulator of uterine cancer progression.
  • miR-126-5p represents a promising therapeutic target for uterine cancer.
  • This study supports the development of miRNA-based treatments for uterine cancer.
Keywords:
GrowthHelaIshikawaMiR-126-5pMigration

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.5K
A Reporter Assay to Analyze Intronic microRNA Maturation in Mammalian Cells06:48

A Reporter Assay to Analyze Intronic microRNA Maturation in Mammalian Cells

Published on: June 16, 2022

1.9K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.0K